| EPB108 | Incidence of cardiometabolic outcomes among people living with HIV initiated on INSTI versus non-INSTI antiretroviral therapies | E-poster | Metabolic, lipid and endocrine complications (including lipodystrophy) |
| EPB109 | Lipid parameters and lipid modifying agent use in participants initiating F/TAF or F/TDF for PrEP in the DISCOVER trial | E-poster | Metabolic, lipid and endocrine complications (including lipodystrophy) |
| EPB110 | Weight gain after antiretroviral therapy initiation in people living with HIV | E-poster | Weight gain |
| EPB111 | Can ART switch mitigate or reverse INSTI-related weight or BMI gain in at-risk people living with HIV-1? | E-poster | Weight gain |
| EPB112 | Switching ART Regimens is associated with greater weight gain in people living with HIV | E-poster | Weight gain |
| EPB113 | Perceptions of health, body size and nutritional risk factors for obesity among people with and without HIV in South Africa | E-poster | Weight gain |
| EPB114 | Weight change when discontinuing integrase strand transfer inhibitors in people living with HIV | E-poster | Weight gain |
| EPB115 | Weight gain after non-nucleoside reverse transcriptase-to-integrase inhibitor switch in the United States | E-poster | Weight gain |
| EPB116 | Change in weight and BMI associated with switching to bictegravir/emtricitabine/tenofovir alafenamide vs. a dolutegravir-based regimen among a prospective longitudinal cohort of virologically suppressed adults living with HIV | E-poster | Weight gain |
| EPB117 | Preferences for weight gain compared with other antiretroviral therapy side effects among people living with HIV: a discrete choice experiment | E-poster | Weight gain |